Arbutus cuts workforce 24%, extends cash runway to Q1 2026; CEO to retire

Arbutus Biopharma Corp

Workforce reduced by 24% affecting research; one-time charge ~$1.1M in Q4 2023.
Cash, cash equivalents & investments $144.7M as of Sep 30; cash runway extended into Q1 2026.
Net loss $20.1M ($0.12 per share) for Q3 2023 vs. $17.6M loss in Q3 2022.
CEO William Collier to retire at end of 2023; COO Michael McElhaugh to serve as interim CEO.
Preliminary Phase 2a data for imdusiran + VTP-300 at AASLD; AB-101 Phase 1a/1b dosing continues.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arbutus Biopharma Corp reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-23-006796

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.